These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 34907179)

  • 1. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
    Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
    Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
    Sun R; Liu Z; Qiu B; Chen T; Li Z; Zhang X; Xu Y; Zhang Z
    EBioMedicine; 2019 Sep; 47():142-155. PubMed ID: 31492557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
    Xu L; Wang P; Zhang W; Li W; Liu T; Che X
    Front Oncol; 2021; 11():757498. PubMed ID: 34660327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc.
    Li Z; Liu J; Chen T; Sun R; Liu Z; Qiu B; Xu Y; Zhang Z
    J Exp Clin Cancer Res; 2021 Mar; 40(1):86. PubMed ID: 33648560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
    Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
    Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
    Schramm C; Sapuk A; Hoyer D; Radünz S; Schmidt H
    Z Gastroenterol; 2024 Jan; 62(1):37-42. PubMed ID: 38195106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMAD4 regulates the progression of cholangiocarcinoma by modulating the expression of STING1.
    Shi AD; Zhao LM; Sheng GL; Zhang GN; Tang YC; Li KS; Zhang ZL
    J Cell Mol Med; 2023 Sep; 27(17):2547-2561. PubMed ID: 37488750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.
    Liu J; Ren G; Li K; Liu Z; Wang Y; Chen T; Mu W; Yang X; Li X; Shi A; Zhao W; Xu B; Chang J; Guo S; Pan C; Zhou T; Zhang Z; Xu Y
    Cell Death Differ; 2022 Apr; 29(4):818-831. PubMed ID: 34799729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
    Ilyas SI; Gores GJ
    Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
    Izquierdo-Sanchez L; Lamarca A; La Casta A; Buettner S; Utpatel K; Klümpen HJ; Adeva J; Vogel A; Lleo A; Fabris L; Ponz-Sarvise M; Brustia R; Cardinale V; Braconi C; Vidili G; Jamieson NB; Macias RI; Jonas JP; Marzioni M; Hołówko W; Folseraas T; Kupčinskas J; Sparchez Z; Krawczyk M; Krupa Ł; Scripcariu V; Grazi GL; Landa-Magdalena A; Ijzermans JN; Evert K; Erdmann JI; López-López F; Saborowski A; Scheiter A; Santos-Laso A; Carpino G; Andersen JB; Marin JJ; Alvaro D; Bujanda L; Forner A; Valle JW; Koerkamp BG; Banales JM
    J Hepatol; 2022 May; 76(5):1109-1121. PubMed ID: 35167909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic classification of cholangiocarcinoma: New concepts.
    Nakanuma Y; Kakuda Y
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells.
    Pan S; Hu Y; Gan L; Lai J; Zheng P; Zhang Y; Shuai L; Jiang Y; Chen M; Wang J; He Y
    Ann Hepatol; 2024; 29(2):101279. PubMed ID: 38123132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
    Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
    Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination.
    Zhang C; Wang Y; Wu G; Sun N; Bai H; Li X; Han S; Zhou H; Qi R; Zhang J
    Biol Direct; 2024 Feb; 19(1):16. PubMed ID: 38395908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
    Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
    Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
    Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
    Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.